Company
Repligen Corporation
Headquarters: Waltham, MA, United States
Founded: 1981
Employees: 1,852
CEO: Mr. Anthony J. Hunt
Market Cap
$9.41 Billion
USD as of Jan. 1, 2025
Repligen Corporation Categories
United States Healthcare Medical Instruments & SuppliesUnited States Healthcare United States Medical Instruments & Supplies
Top Competitors by Market Capitalization
Industry: Medical Instruments & Supplies
| Company | Market Cap (USD) |
|---|---|
| Intuitive | $216.79 B |
| EssilorLuxottica SA | $116.96 B |
| Becton, Dickinson and Company | $69.74 B |
| HOYA Corp | $45.26 B |
| Alcon Inc. | $41.55 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Financials
| Last Financial Reports Date | Sept. 30, 2024 |
| Revenue TTM | $639.9 M |
| EBITDA | $67.5 M |
| Gross Profit TTM | $327.6 M |
| Profit Margin | -0.33% |
| Operating Margin | -2.22% |
| Quarterly Revenue Growth | 9.70% |
Stocks & Indices
Repligen Corporation has the following listings and related stock indices.
Stock: NASDAQ: RGEN wb_incandescent
Stock: FSX: RGN wb_incandescent
Product & Services
Materials used in the manufacture of biological drugs
Key People
Founder(s): Alexander Rich Paul Schimmel
Tony J. Hunt (President) and CEO)